Cantor Fitzgerald Reiterates Overweight on Bicycle Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a $65 price target.
September 07, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Bicycle Therapeutics and maintained a $65 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Bicycle Therapeutics. The maintained price target of $65 suggests that the analyst believes the stock is undervalued at current prices, which could lead to upward pressure on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100